All In Biotech

Drug Trial Radar · NCT05436639

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jul 1, 2023

Primary completion

Dec 1, 2024

Study completion Feb 18, 2025

Sponsor

Lead sponsor
Sparrow PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.

Conditions

  • Autonomous Cortisol Secretion (ACS)
  • ACTH-Independent Cushing Syndrome
  • ACTH-Independent Adrenal Cushing Syndrome, Somatic

Interventions

  • SPI-62 doseDrug

    SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (2mg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c at Week 6Time frame: Baseline to week 6
  2. Change in HbA1c at week 12Time frame: Baseline to week 12

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Cancer Center (MCCC) - Rochester

    Rochester, Minnesota

  • Ohio State McCampbell Outpatient Care

    Columbus, Ohio

  • C.M.D.T.A. Neomed

    Brasov, Romania

  • Institutul National de Endocrinologie

    Bucharest, Romania

  • King's College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.